重要新闻提示 114种新药进入2025年国家医保药品目录，恒瑞医药、复星医药等多家A股医药龙头宣布产品获纳入 古鳌科技：实控人筹划公司控制权变更事项，公司股票自12月8日起停牌 沐曦股份：网上发行最终中签率为0.03348913% 今日提示 创业板新股纳百川（申购代码：301667）今日申购，发行价为22.63元/股 科创板新股优迅股份（申购代码：787870）今日申购，发行价为51.66元/股 纳芯微H股今日在香港联交所挂牌并开始上市交易 《证券结算风险基金管理办法》12月8日起施行 12月8日24时国内成品油将开启新一轮调价窗口 今日央行公开市场有1076亿元7天期逆回购到期 2025·人工智能+未来产业发展大会12月8日—9日在广州举办 财经新闻 1. 12月7日，医保、商保"双目录"发布。国家医保局、人力资源社会保障部印发《国家基本医疗保险、 生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》（2025年）。新版目录将于2026年 1月1日在全国范围内正式实施。本次调整后，2025年国家医保药品目录内药品总数增至3253种，其中西 药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - The company has shown significant revenue growth, achieving a total revenue of 1.806 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 42.06%. In the third quarter alone, revenue reached 637 million yuan, up 31.40% year-on-year [2][4][8]. - The core commercial product, Tuoyi® (Tremelimumab), generated approximately 1.495 billion yuan in sales, marking a year-on-year growth of about 40%. The expansion of indications has further driven revenue growth [8]. - The company is on the verge of a harvest period with its core pipeline products, including JS207, JS005, and JS107, demonstrating clinical value [2][8]. Summary by Sections Revenue Performance - In the first three quarters of 2025, the company achieved a revenue of 1.806 billion yuan, a 42.06% increase year-on-year. The third quarter revenue was 637 million yuan, reflecting a 31.40% year-on-year growth [4][8]. Product Commercialization - The revenue growth is primarily driven by Tuoyi® (Tremelimumab), which achieved sales of approximately 1.495 billion yuan in the first three quarters of 2025, a 40% increase year-on-year. The product has received regulatory acceptance for new indications, enhancing its market potential [8]. Pipeline Development - The company has over 50 pipeline products covering five major therapeutic areas: oncology, autoimmune diseases, chronic metabolism, neurology, and infections. Key products like JS207 and JS005 are progressing through clinical trials, with JS207 receiving FDA approval for a clinical trial in non-small cell lung cancer [8].